Retrospective evaluation of the clinical benefit of long-term continuous use of zoledronic acid in patients with lung cancer and bone metastases

Background: Zoledronic acid every 4 weeks (Q4wk) reduces the incidence of skeletal-related events (SREs) in patients with metastatic lung cancer. Lung cancer patients were excluded from extended-interval dosing trials (every 12 weeks [Q12wk]) that demonstrated noninferiority of the 2 dosing schemes. To date, the optimal dosing of zoledronic acid in metastatic lung cancer remains unknown. Objective: To determine whether zoledronic acid dosed Q12wk is similar to Q4wk dosing for prevention of SRE in patients with metastatic lung cancer. Methods: A retrospective analysis was performed in patients with non–small-cell lung cancer and small-cell lung cancer with bone metastases who received Q12wk and Q4wk zoledronic acid. The primary outcome was incidence of SRE at 1 year. Secondary analyses included time to first SRE, overall survival (OS), incidence of osteonecrosis of the jaw (ONJ), kidney dysfunction, and hypocalcemia. Results: A total of 34 patients received Q12wk and 46 patients received Q4wk zoledronic acid. Incidence of SRE at 1 year (Q12wk, 23.5%, vs Q4wk, 23.9%; 95% CI = −0.184 to 0.192; P = 0.968) and median time to SRE (not reached for either cohort; P = 0.530) did not differ. The Q12wk cohort had longer median OS (24.00 vs 8.97 months; P = 0.022). There were no differences in incidence of ONJ, kidney dysfunction, and hypocalcemia. Conclusion and Relevance: This is the first report examining extended-interval dosing of zoledronic acid in metastatic lung cancer. Incidence and time to SRE at 1 year were similar. This extended-interval dosing may be safe and reasonable for patients with lung cancer with bone metastases.

Download Full-text

Preclinical Murine Models for Lung Cancer: Clinical Trial Applications

BioMed Research International ◽

10.1155/2015/621324 ◽

2015 ◽

Vol 2015 ◽

pp. 1-17 ◽

Cited By ~ 55

Author(s):

Amelia Kellar ◽

Cay Egan ◽

Don Morris

Keyword(s):

Lung Cancer ◽

Clinical Trial ◽

Clinical Benefit ◽

Therapeutic Strategy ◽

Chemotherapeutic Agents ◽

Future Research ◽

Murine Models ◽

Retrospective Evaluation ◽

Experimental Systems ◽

Early Human

Murine models for the study of lung cancer have historically been the backbone of preliminary preclinical data to support early human clinical trials. However, the availability of multiple experimental systems leads to debate concerning which model, if any, is best suited for a particular therapeutic strategy. It is imperative that these models accurately predict clinical benefit of therapy. This review provides an overview of the current murine models used to study lung cancer and the advantages and limitations of each model, as well as a retrospective evaluation of the uses of each model with respect to accuracy in predicting clinical benefit of therapy. A better understanding of murine models and their uses, as well as their limitations may aid future research concerning the development and implementation of new targeted therapies and chemotherapeutic agents for lung cancer.

Download Full-text

615 Long-term efficacy and safety of zoledronic acid in men with advanced prostate cancer and bone metastases

European Urology Supplements ◽

10.1016/s1569-9056(04)90609-4 ◽

2004 ◽

Vol 3 (2) ◽

pp. 156 ◽

Cited By ~ 9

Author(s):

F. Saad ◽

D. Gleason ◽

R. Murray ◽

P. Venner ◽

S. Tchekmedyian ◽

...

Keyword(s):

Prostate Cancer ◽

Zoledronic Acid ◽

Bone Metastases ◽

Advanced Prostate Cancer ◽

Efficacy And Safety ◽

Term Efficacy

Download Full-text

Effects of intravenous zoledronic acid and oral ibandronate on early changes in markers of bone turnover in patients with bone metastases from non-small cell lung cancer

International Journal of Clinical Oncology ◽

10.1007/s10147-010-0179-x ◽

2011 ◽

Vol 16 (3) ◽

pp. 264-269 ◽

Cited By ~ 12

Author(s):

Filippo Francini ◽

Alessandra Pascucci ◽

Gianluca Bargagli ◽

Edoardo Francini ◽

Raffaele Conca ◽

...

Keyword(s):

Lung Cancer ◽

Zoledronic Acid ◽

Bone Turnover ◽

Small Cell Lung Cancer ◽

Bone Metastases ◽

Cell Lung Cancer ◽

Small Cell ◽

Small Cell Lung ◽

Markers Of Bone Turnover

Download Full-text

Renal safety of zoledronic acid administration beyond 24 months in breast cancer patients with bone metastases

Journal of Clinical Oncology ◽

10.1200/jco.2007.25.18_suppl.19669 ◽

2007 ◽

Vol 25 (18_suppl) ◽

pp. 19669-19669

Author(s):

M. K. Altundag ◽

M. Dincer ◽

H. Harputluoglu ◽

S. Aksoy ◽

Y. Ozisik ◽

...

Keyword(s):

Breast Cancer ◽

Zoledronic Acid ◽

Bone Metastases ◽

Cancer Patients ◽

Breast Cancer Patients ◽

Skeletal Complications ◽

Few Data ◽

Acid Administration ◽

Renal Safety

19669 Background: Zoledronic acid (ZA) delays the onset or reduces the incidence of skeletal complications in breast cancer patients with bone metastases. However there are few data on the long-term renal safety of ZA. Methods: We retrospectively evaluated 43 breast cancer patients with bone metastases who received ZA more than 24 months. The following parameters measured prior to first ZA use and after the last dose of ZA administration were compared: serum creatinine (SCr), blood urea nitrogen (BUN), alkaline phosphatase (ALP), calcium (Ca), and phosphorous (P). Results: Forty-three breast cancer patients with documented bone metastases were evaluated. Median age at the start of treatment was 53 years (range, 37 to 77). Median overall duration of ZA administration was 36 months (25 to 62). There were no statistically significant differences in the pre- and post-treatment levels of SCr, BUN, Ca and P. However, ALP levels after long-term ZA administration were decreased significantly (P <0.05). Conclusion: More than 24 months of ZA administration did not adversely affect the renal function. ZA can be used safely in breast cancer patients with bone metastases beyond 2 years. [Table: see text] No significant financial relationships to disclose.

Download Full-text